The STEP 2 trial, conducted in patients with type 2 diabetes, demonstrated even greater triglyceride reductions (averaging 20-25%), likely reflecting the baseline metabolic dysfunction in this population
Key Results: What the Data Shows Primary Endpoint: Weight Loss The 12mg retatrutide group achieved 28.3% average weight loss at 80 weeks compared to approximately 2% in the placebo group
CagriSema asks whether adding amylin biology to semaglutide can extend the GLP-1 era
While the precise reason has not yet been determined, its most likely a side effect of the weight loss itself, not the medication
Det er nogle af de hjeste vgttabsresultater nogensinde vist for et enkelt farmakologisk middel i kliniske studier
Peptide therapy is great for anyone wanting to look, feel, and perform their best